M42与AstraZeneca和SOPHIA基因组织伙伴一起,在阿联酋启动了液体生物癌测试。 M42, with partners AstraZeneca and SOPHiA Genetics, launches liquid biopsy cancer testing in the UAE.

M42与AstraZeneca和SOPHIA基因公司合作,正在阿联酋引入液体生物检查,以加强癌症诊断和治疗决定。 M42, in partnership with AstraZeneca and SOPHiA Genetics, is introducing liquid biopsy testing in the UAE to enhance cancer diagnosis and treatment decisions. 这一技术使用简单的抽血来进行基因组特征分析,针对多种癌症,包括肺癌、乳腺癌和直肠癌。 This technology, which uses a simple blood draw for genomic profiling, targets multiple cancers including lung, breast, and colorectal. 在克利夫兰阿布扎比诊所进行的初步验证研究将导致在2025年在Q2全面启动,并计划扩大中东。 Initial validation studies at Cleveland Clinic Abu Dhabi will lead to a full launch in Q2 2025, with plans for broader Middle Eastern expansion.